Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
CgPdr1p is a Candida glabrata Zn(2)-Cys(6) transcription factor involved in the regulation of the ABC-transporter genes CgCDR1, CgCDR2, and CgSNQ2, which are mediators of azole resistance. Single-point mutations in CgPDR1 are known to increase the expression of at least CgCDR1 and CgCDR2 and thus to contribute to azole resistance of clinical isolates. In this study, we investigated the incidence of CgPDR1 mutations in a large collection of clinical isolates and tested their relevance, not only to azole resistance in vitro and in vivo, but also to virulence. The comparison of CgPDR1 alleles from azole-susceptible and azole-resistant matched isolates enabled the identification of 57 amino acid substitutions, each positioned in distinct CgPDR1 alleles. These substitutions, which could be grouped into three different "hot spots," were gain of function (GOF) mutations since they conferred hyperactivity to CgPdr1p revealed by constitutive high expression of ABC-transporter genes. Interestingly, the major transporters involved in azole resistance (CgCDR1, CgCDR2, and CgSNQ2) were not always coordinately expressed in presence of specific CgPDR1 GOF mutations, thus suggesting that these are rather trans-acting elements (GOF in CgPDR1) than cis-acting elements (promoters) that lead to azole resistance by upregulating specific combinations of ABC-transporter genes. Moreover, C. glabrata isolates complemented with CgPDR1 hyperactive alleles were not only more virulent in mice than those with wild type alleles, but they also gained fitness in the same animal model. The presence of CgPDR1 hyperactive alleles also contributed to fluconazole treatment failure in the mouse model. In conclusion, this study shows for the first time that CgPDR1 mutations are not only responsible for in vitro/in vivo azole resistance but that they can also confer a selective advantage under host conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region) were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.](https://figures.cochat.ai/paper-figures/69b6baffc71c4842aa873ef304106b27/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-2.jpg)

![Figure 4 Effect of CgPDR1 expression on azole resistance. (A) Expression of CgPDR1 in a matched pair of azole-susceptible and azole-resistant isolates (DSY2235 and DSY2234), in revertant strains (“rev”) overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1Δ mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each strain (“DSY” for clinical strains and “rev” for revertant strains) were named according to their strain number origin. RNA was isolated from log phase cultures, slot-blotted to membranes, and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1 and substracted from background. Expression values represent the increase of CgPDR1 expression in revertant strains relative to the clinical isolates expressing the same CgPDR1 allele. (B) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235 and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and of a pdr1Δ mutant (SFY53). Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY2235 and DSY2234, in revertant strains (rev) overexpressing CgPDR1 alleles in a pdr1Δ mutant (SFY53). Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document (National Committee for Clinical Laboratory Standards, 2002).](https://figures.cochat.ai/paper-figures/ac16b99890e140cf9efad3769d9335b6/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-4.jpg)
![Figure 5 Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1Δ: SFY92; DSY565 pdr1Δ: SFY94; DSY562 pdr1Δ+562 (standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1Δ+565L280F (standing for re-introduction of CgPDR1 from DSY565 with L280F substitution): SFY115; DSY565pdr1Δ+562: SFY118; DSY565 pdr1Δ+565L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.](https://figures.cochat.ai/paper-figures/22fe62baf08b4a8880e792810b2a746e/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-5.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The authors also indicate that the altered cellular sterol composition of CG156 may affect intracellular signalling and trafficking pathways, as the efflux machinery [199,211,212] and any transport proteins that are proposed to mediate azole import via facilitated diffusion [213].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other cases of induced cross-resistance to azole drugs in C. glabrata were related to resistance against both azoles and amphotericin B [198,199,212] and related to prochloraz (an agricultural antifungal).”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BPY41 exhibited mitochondrial dysfunction”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“however, it is not dependent on the presence of GOF mutations in *CgPDR1* ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784 · cited 1×
“efflux pumps (for review, see [7]).”
Self-citationThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“mutations in genes involved in antibiotic resistance can be beneficial in the fitness of pathogenic bacteria [30,31].”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“The consensus motif is named PDRE (for pleiotropic drug resistance element) and is present in several ABC-transporter gene promoters such as PDR5, SNQ2 and YOR1 [25].”
BackgroundThe biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472 · cited 1×
“Restoration of fitness in drugresistant bacteria is often associated with the emergence of compensatory mutations [29].”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423 · cited 1×
“during patient treatment [4–6].”
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · cited 2×
“In bacteria, antimicrobial resistance is often associated with fitness costs and thus results in a competitive disadvantage against otherwise drug-susceptible bacteria within the host [28].”
BackgroundA nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343 · cited 1×
“. CgPdr1p acts as nuclear receptor by directly binding to diverse drugs and xenobiotics, such as azoles, to activate expression of efflux pumps genes resulting in multidrug resistance”
BackgroundSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 5×
“glabrata was performed as previously described [10].”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 101–200 of 291
Costa, C., Nunes, J., Henriques, A., Mira, N. P., Nakayama, H., Chibana, H., & Teixeira, M. C. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku044 · Cited by 41
Schubert, S., Popp, C., Rogers, P. D., & Morschhäuser, J. (2011) · Eukaryotic Cell · doi:10.1128/ec.05100-11 · Cited by 39
Eddouzi, J., Lohberger, A., Vogne, C., Manaï, M., & Sanglard, D. (2013) · Medical Mycology · doi:10.3109/13693786.2013.800239 · Cited by 48
Self-citationMechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China
Yao, D., Chen, J., Chen, W., Li, Z., & Hu, X. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s202058 · Cited by 42
“Among the 4 missense mutations, G1042T (G348C) and A2290G (N764D) have been reported previously.(25) Although G2626A (D876N) has also been reported, the amino acid mutation was different.”
Cheng, S., Clancy, C. J., Hartman, D. J., Hao, B., & Nguyen, M. H. (2014) · Infection and Immunity · doi:10.1128/iai.00062-14 · Cited by 38
Ni, Q., Wang, C., Tian, Y., Dong, D., Jiang, C., Mao, E., & Peng, Y. (2018) · Mycoses · doi:10.1111/myc.12756 · Cited by 37
Biswas, C., Chen, S. C.-A., Halliday, C., Kennedy, K., Playford, E. G., Marriott, D. J., Slavin, M. A., Sorrell, T. C., & Sintchenko, V. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.014 · Cited by 36
“confer multi-azole resistance [20, 21] as was found herein with the identification of several 179 SNPs in CgPDR1.”
BackgroundCandida glabrata’s Genome Plasticity Confers a Unique Pattern of Expressed Cell Wall Proteins
López-Fuentes, E., Gutiérrez-Escobedo, G., Timmermans, B., Van Dijck, P., De Las Peñas, A., & Castaño, I. (2018) · Journal of Fungi · doi:10.3390/jof4020067 · Cited by 35
“Together these genes conform the pleiotropic drug resistance (PDR) network [41,53,54,57,58].”
BackgroundFitness Studies of Azole-Resistant Strains of Aspergillus fumigatus
Valsecchi, I., Mellado, E., Beau, R., Raj, S., & Latgé, J.-P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01594-15 · Cited by 35
“deed been demonstrated for only very few yeast strains (22, 23).”
BackgroundABC proteins in yeast and fungal pathogens
Klein, C., Kuchler, K., & Valachovič, M. (2011) · Essays in Biochemistry · doi:10.1042/bse0500101 · Cited by 38
“glabrata azole‐resistant strains [35].”
Barber, A. E., Weber, M., Kaerger, K., Linde, J., Gölz, H., Duerschmied, D., Markert, A., Guthke, R., Walther, G., & Kurzai, O. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01628-18 · Cited by 32
“However, we did identify a novel R761M polymorphism in this gene not previously described among the sequences present in the GenBank nr collection, in addition to V91I, L98S, and D243N polymorphisms which have been previously described in both azole-susceptible and azole-resistant isolates (22).”
BackgroundPais, P., Costa, C., Cavalheiro, M., Romão, D., & Teixeira, M. C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00131 · Cited by 37
“On the other hand, infections by the pathogenic yeast Cryptococcus neoformans are primarily pulmonary, persisting for long periods of time, and then spreading to the central nervous system (CNS) (Hole and Wormley, 2016).”
BackgroundSalazar, S. B., Wang, C., Münsterkötter, M., Okamoto, M., Takahashi-Nakaguchi, A., Chibana, H., Lopes, M. M., Güldener, U., Butler, G., & Mira, N. P. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/fox079 · Cited by 31
“Three of these SNPs (Val91Ile; Leu98Ser and Asp243Asn) were found to be present simultaneously in the CgPDR1 alleles encoded by isolates resistant and susceptible to azoles (Ferrari et al., 2009). while the Lys274Gln was not previously described.”
BackgroundInfluentialLi, L., Liao, Z., Yang, Y., Lv, L., Cao, Y., & Zhu, Z. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192328 · Cited by 35
Using genomics to understand the mechanisms of virulence and drug resistance in fungal pathogens
Schikora-Tamarit, M. À., & Gabaldón, T. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211123 · Cited by 35
Faria‐Ramos, I., Tavares, P. R., Farinha, S., Neves-Maia, J., Miranda, I. M., Silva, R. M., Estevinho, L. M., Pina‐Vaz, C., & Rodrigues, A. G. (2014) · FEMS Yeast Research · doi:10.1111/1567-1364.12193 · Cited by 38
“…was found at PDR1 while ERG11 only showed the existence of several synonymous SNPs suggesting that this gene was not involved in C. glabrata azole resistance in the isolate examined (Ferrari et al., 2009; Sanguinetti et al., 2005) A cc ep te d A rt ic le This article is protected by copyright.”
BackgroundInfluentialGarcia-Rubio, R., Jimenez-Ortigosa, C., DeGregorio, L., Quinteros, C., Shor, E., & Perlin, D. S. (2021) · mBio · doi:10.1128/mbio.01959-21 · Cited by 29
Moye-Rowley, S. (2018) · Current Genetics · doi:10.1007/s00294-018-0870-4 · Cited by 32
Vu, B. G., & Moye-Rowley, S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02098-21 · Cited by 33
Candida glabrata is a successful pathogen: An artist manipulating the immune response
Castrejón-Jiménez, N. S., Castillo-Cruz, J., Baltierra‐Uribe, S. L., Hernández-González, J. C., & Estela, G.-P. B. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127038 · Cited by 37
Gale, A. N., Pavesic, M. W., Nickels, T. J., Xu, Z., Cormack, B. P., & Cunningham, K. W. (2023) · mSphere · doi:10.1128/msphere.00254-23 · Cited by 27
“glabrata also exhibited hyper-vir ulence in mouse models of invasive candidiasis even in the absence of antifungals (9, 20, 21).”
BackgroundUsher, J., & Haynes, K. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008259 · Cited by 27
“glabrata strains harbouring PDR1 mutations exhibit increased virulence [18] implying adaptation within the host to antifungals may itself enhance the ability of C.”
BackgroundBreda, G. L., Tuon, F. F., Meis, J. F. G. M., Herkert, P. F., Hagen, F., de Oliveira, L. Z., Dias, V. D. C., da Cunha, C. A., & Queiroz‐Telles, F. (2017) · Medical Mycology · doi:10.1093/mmy/myx077 · Cited by 29
Khakhina, S., Simonicova, L., & Moye‐Rowley, W. S. (2018) · Molecular Microbiology · doi:10.1111/mmi.13913 · Cited by 32
“Substitution mutant derivatives of Pdr1 were identified in clinical isolates using congenic strains that varied in their level of fluconazole resistance (Ferrari et al., 2009).”
BackgroundResultInfluentialRai, M. N., Sharma, V., Balusu, S., & Kaur, R. (2014) · Cellular Microbiology · doi:10.1111/cmi.12364 · Cited by 31
“glabrata burden and mice survival data (Ferrari et al., 2009).”
ResultVandeputte, P., Tronchin, G., Rocher, F., Renier, G., Bergès, T., Chabasse, D., & Bouchara, J.-P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01384-08 · Cited by 26
“For example, the Y584C mutation leads to the upregulation of CDR1 but does not affect CDR2 expression, as was observed in our clinical isolate (14).”
BackgroundAbbes, S., Mary, C., Sellami, H., Michel-Nguyen, A., Ayadi, A., & Ranque, S. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00074 · Cited by 29
“Indeed, mutations in CgPDR1, CgERG11 or others genes that might impact C. glabrata fluconazole resistance were not analyzed in this study.”
BackgroundExpression Patterns of ABC Transporter Genes in Fluconazole-Resistant Candida glabrata
Gohar, A. A., Badali, H., Shokohi, T., Nabili, M., Amirrajab, N., & Moazeni, M. (2017) · Mycopathologia · doi:10.1007/s11046-016-0074-8 · Cited by 25
“According to the literature, the W297S, F575L, P927L, Y584C, and T588A amino acid substitutions are responsible for constitutive overexpression of CgCDR1 and CgCDR2, and the P822L substitution was shown to be responsible for the overexpression of CgSNQ2 only [37].”
BackgroundCandida parapsilosis Sensu Stricto Antifungal Resistance Mechanisms and Associated Epidemiology
Franconi, I., Rizzato, C., Poma, N. V., Tavanti, A., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9080798 · Cited by 29
“To this point, the most frequently reported gene hosting in vivo mutations in azole-resistant Candida albicans and Candida glabrata strains is ERG11 [56,63,64].”
BackgroundTati, S., Jang, W. S., Li, R. Q., Kumar, R., Puri, S., & Edgerton, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061480 · Cited by 29
Novel Regulatory Mechanisms of Pathogenicity and Virulence to Combat MDR inCandida albicans
Hameed, S., & Fatima, Z. (2013) · International Journal of Microbiology · doi:10.1155/2013/240209 · Cited by 29
Kodedová, M., & Sychrová, H. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.06.005 · Cited by 27
Molecular analysis of Candida glabrata clinical isolates
Berila, N., & Šubík, J. (2010) · Mycopathologia · doi:10.1007/s11046-010-9298-1 · Cited by 24
“glabrata clinical isolates [9, 10, 20].”
Sturm, L., Geißel, B., Martin, R., & Wagener, J. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01017 · Cited by 26
“This involves the increased expression of multiple efflux pumps (Traven et al., 2001; Tsai et al., 2006; Gulshan et al., 2008; Ferrari et al., 2009, 2011a,b; Shingu-Vazquez and Traven, 2011).”
BackgroundOttilie, S., Luth, M. R., Hellemann, E., Goldgof, G. M., Vigil, E., Kumar, P., Cheung, A. L., Song, M., Godinez‐Macias, K. P., Carolino, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03076-7 · Cited by 29
Candida glabrata, Friend and Foe
Tam, P., Gee, K., Piechocinski, M., & Macreadie, I. G. (2015) · Journal of Fungi · doi:10.3390/jof1020277 · Cited by 29
“binding cassette (ABC) transporter superfamily or the major facilitator (MDR) superfamily [32].”
BackgroundBorah, S., Shivarathri, R., Srivastava, V. K., Ferrari, S., Sanglard, D., & Kaur, R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02786-14 · Cited by 23
“hanced virulence in murine models (17).”
BackgroundSelf-citationWhole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Biswas, C., Chen, S. C. ‐., Halliday, C. L., Martinez, E. M., Rockett, R. J., Wang, Q., Timms, V. J., Dhakal, R., Sadsad, R., Kennedy, K., et al. (2017) · Journal of Visualized Experiments · doi:10.3791/56714 · Cited by 23
Jjj1 Is a Negative Regulator of Pdr1-Mediated Fluconazole Resistance in Candida glabrata
Whaley, S. G., Caudle, K. E., Simonicova, L., Zhang, Q., Moye-Rowley, W. S., & Rogers, P. D. (2018) · mSphere · doi:10.1128/msphere.00466-17 · Cited by 22
Moirangthem, R., Kumar, K., & Kaur, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02415-20 · Cited by 20
“The CgPdr1 transcriptional activator is also implicated in the expression regulation of virulence-related genes (12, 18, 22).”
BackgroundMaroc, L., Shaker, H., & Shapiro, R. S. (2024) · mSphere · doi:10.1128/msphere.00761-23 · Cited by 22
“We focused on PDR1 , encoding a transcrip tional regulator of a pleiotropic drug resistance network in N. glabrata , whose overex pression is known to play a role in resistance to azole antifungals in clinical isolates (16, 53–55).”
BackgroundMolecular Typing of Candida glabrata
Gabaldón, T., Gómez-Molero, E., & Bader, O. (2019) · Mycopathologia · doi:10.1007/s11046-019-00388-x · Cited by 26
Self-citationThe Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_29 · Cited by 24
“GOF mutations in the transcription factor Pdr1 induce the overexpression of the ABC efflux pumps Cdr1, Snq2, and Pdh1 (Torelli et al. 2008; Tsai et al. 2006; Ferrari et al. 2009) and may also overexpress the MFS transporter Qdr2, since the QDR2 gene has been shown to be induced through Pdr1 in the presence of azoles (…”
BackgroundEvaluation of Polymorphic Locus Sequence Typing for Candida glabrata Epidemiology
Katiyar, S. K., Shiffrin, E., Shelton, C. A., Healey, K. R., Vermitsky, J., & Edlind, T. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.03106-15 · Cited by 22
“In support of its role in resistance, the Lys274Glu substitution is within a Pdr1 region in which multiple other resistance-conferring mutations have been mapped (17), while the 5 other substitutions (between residues Ser76 and Thr143) are upstream of any known resistance-conferring mutation.”
BackgroundResultInfluentialXenobiotic Efflux in Bacteria and Fungi: A Genomics Update
Barabote, R. D., Thekkiniath, J., Strauss, R. E., Vediyappan, G., Fralick, J. A., & Francisco, M. J. S. (2011) · Advances in enzymology and related areas of molecular biology/Advances in enzymology and related subjects · doi:10.1002/9780470920541.ch6 · Cited by 26
Shor, E., Schuyler, J., & Perlin, D. S. (2019) · mBio · doi:10.1128/mbio.00120-19 · Cited by 19
“However, as described above, comparisons of different clinical isolates are complicated by the variation in their drug resistance profiles, some of which is due to varying activity of drug efflux pumps (14, 15, 18), which is likely to render any drug resistance-based mutation assay inapplicable.”
Stress Response in Candida Glabrata : Pieces of a Fragmented Picture
Jandric, Z., & Schüller, C. (2011) · Future Microbiology · doi:10.2217/fmb.11.131 · Cited by 19
The challenges of the genome-based identification of antifungal resistance in the clinical routine
Alastruey‐Izquierdo, A., & Martín-Galiano, A. J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1134755 · Cited by 20
Misas, E., Seagle, E. E., Jenkins, E. N., Rajeev, M., Hurst, S. F., Nunnally, N. S., Bentz, M. L., Lyman, M., Berkow, E. L., Harrison, L. H., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-23 · Cited by 26
Lim, H. J., Shin, J. H., Kim, M., Yong, D., Byun, S. A., Choi, M. J., Lee, S. Y., Won, E. J., Kee, S., Kim, S. H., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00740-20 · Cited by 20
“glabrata is mostly governed by a single mechanism through a gain-of-function mutation in the transcription factor for Pdr1p, regulating the drug-efflux transporter genes (20).”
BackgroundCulakova, H., Džugasová, V., Perzelova, J., Gbelská, Y., & Šubík, J. (2013) · Yeast · doi:10.1002/yea.2978 · Cited by 20
“…of CgPDR1 (and its target genes) due to its gain-of-function mutations (Vermitsky and Edlind, 2004; Tsai et al., 2006; Berila et al., 2009; Ferrari et al., 2009, 2011), cell surface hydrophobicity (CSH) and biofilm formation are well-recognized virulence factors in C. glabrata (Kaur et…”
BackgroundKodedová, M., & Sychrová, H. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.06.023 · Cited by 18
“14 We were interested in whether this resistance of DSY565 could be caused by the activity of multidrug resistance (MDR) pumps, since this strain contains a gain-of-function mutation in CgPDR1, which conferred the hyperactivity of CgPdr1p, resulting in a constitutive high expression of ABC-transporter genes (Ferrari e…”
BackgroundPfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 22
“In addition to GOF mutations in CgPDR1, several genes involved in stress response, resistance to DNA damage, and cell wall structure are upregulated in azole-resistant strains of C. glabrata, all of which may contribute individually or in combination to modulate the virulence of C. glabrata [77].”
InfluentialKlimova, N. G., Yeung, R., Kachurina, N., & Turcotte, B. (2014) · G3 Genes Genomes Genetics · doi:10.1534/g3.113.010199 · Cited by 21
“As observed in S. cerevisiae, mutations in the CgPDR1 gene result in hyperactivation of the transcription factor, causing increased resistance to various drugs such as azoles and, unexpectedly, increased virulence (Berila et al. 2009; Ferrari et al. 2009; Tsai et al. 2006; Vermitsky et al. 2006).”
BackgroundVu, B. G., & Moye-Rowley, W. S. (2018) · mSphere · doi:10.1128/msphere.00099-18 · Cited by 20
“Data also exist that argue these GOF forms of Pdr1 enhance virulence of strains containing these mutant transcription factors (8).”
BackgroundNikolov, V. N., Malavia, D., & Kubota, T. (2022) · Nature Communications · doi:10.1038/s41467-022-29591-z · Cited by 16
Schrevens, S., Durandau, E., Tran, V. D. T., & Sanglard, D. (2022) · Virulence · doi:10.1080/21505594.2022.2095716 · Cited by 17
“glabrata [51], therefore the in vivo profile suggests that C.”
BackgroundSelf-citationGiovati, L., Santinoli, C., Ferrari, E., Ciociola, T., Martín, E., Bandi, C., Ricci, I., Epis, S., & Conti, S. (2018) · Toxins · doi:10.3390/toxins10020068 · Cited by 21
“glabrata SF 116 FluR, DSY562 pdr1∆‐P822L [31] 13 C.”
BackgroundInfluentialGenome-Wide Response to Drugs and Stress in the Pathogenic Yeast Candida glabrata
Pais, P., Galocha, M., & Teixeira, M. C. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_7 · Cited by 18
Genomics in plant pathogen identification and control
Ogbuji, N. G., & Agogbua, J. U. (2025) · Frontiers in Plant Science · doi:10.3389/fpls.2025.1661432 · Cited by 23
Wang, Q., Li, Y., Cai, X., Li, R., Zheng, B., Yang, E., Liang, T., Yang, X., Wan, Z., & Liu, W. (2021) · Antibiotics · doi:10.3390/antibiotics10101217 · Cited by 16
Bhakt, P., Raney, M., & Kaur, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102485 · Cited by 17
Galocha, M., Viana, R., Pais, P., Silva-Dias, A., Cavalheiro, M., Miranda, I. M., Ende, M. V., Souza, C. S., Costa, C., Branco, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04087-0 · Cited by 18
Sethiya, P., Rai, M. N., Rai, R., Parsania, C., Tan, K., & Wong, K. H. (2019) · Fungal Biology · doi:10.1016/j.funbio.2019.12.005 · Cited by 16
Abbes, S., Sellami, H., Néji, S., Trabelsi, H., Makni, F., & Ayadi, M. A. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001236 · Cited by 16
Salazar, S. B., Pinheiro, M. J. F., Sotti-Novais, D., Soares, A. R., Lopes, M. M., Ferreira, T., Rodrigues, V., Fernandes, F., & Mira, N. P. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac110 · Cited by 20
“…strains were CgCDR1 and CgPUP1, the sole 2 CgPdr1 target genes found to be commonly up-regulated in strains encoding different CgPdr1 GOF mutants (Ferrari et al. 2009, 2011) (up-regulation of these 2 genes detected in the microarray experiments was further confirmed by real time RT-PCR,…”
BackgroundInfluentialSteier, Z., Vermitsky, J.-P., Toner, G., Gygax, S. E., Edlind, T., & Katiyar, S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02394-12 · Cited by 14
Wang, Y., Xu, J., Abid, F. B., Salah, H., Sundararaju, S., Ismail, K. A., Wang, K., Matthew, L. S., Taj‐Aldeen, S. J., Ibrahim, E. B., et al. (2024) · Microbial Genomics · doi:10.1099/mgen.0.001179 · Cited by 15
“At least 12 different PDR1 alleles recovered from azole-susceptible isolates contained combinations of eight different mutations and 58 different alleles seemed specific for azole-resistant isolates with 58 distinct mutations [101].”
BackgroundKoren, V., Ben‐Zeev, E., Voronov, I., & Fridman, M. (2024) · JACS Au · doi:10.1021/jacsau.4c00479 · Cited by 13
Vitali, A., Vavala, E., Marzano, V., Leone, C., Castagnola, M., Iavarone, F., & Angiolella, L. (2016) · Journal of Chemotherapy · doi:10.1080/1120009x.2016.1199507 · Cited by 14
Resistencia de levaduras del género Candida al fluconazol
Gómez, C. (2010) · Infectio · doi:10.1016/s0123-9392(10)70134-x · Cited by 27
“con mayor virulencia de la levadura, como ocurre en el caso de C glabrata con sobreexpresión de la mutación CgPDR1 (15).”
BackgroundInfluentialAt What Cost Echinocandin Resistance?
Clancy, C. J., & Nguyen, M. H. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir355 · Cited by 13
Culakova, H., Dzugasova, V., Valencikova, R., Gbelska, Y., & Subik, J. (2015) · Microbiological Research · doi:10.1016/j.micres.2015.03.004 · Cited by 11
Naskar, S., Prajapati, A., & Kaur, R. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf025 · Cited by 17
“This multidrug efflux pump ov er expr ession is lar gel y attributed to gain-of-function mutations in Cg PDR1 gene whose protein product belongs to the zinc-finger family of transcriptional regulators (Ferrari et al. 2009 , Rasheed et al. 2020 ).”
Shahi, G., Kumar, M., Khandelwal, N., Banerjee, A., Sarkar, P., Kumari, S., Esquivel, B. D., Chauhan, N., Chattopadhyay, A., White, T. C., et al. (2022) · Journal of Fungi · doi:10.3390/jof8070651 · Cited by 12
Artemisinin Targets Transcription Factor PDR1 and Impairs Candida glabrata Mitochondrial Function
Zhu, P., Yue, C., Zeng, X., & Chen, X. (2022) · Antioxidants · doi:10.3390/antiox11101855 · Cited by 18
Genomic epidemiology of human candidaemia isolates in a tertiary hospital
Chew, K. L., Achik, R., Osman, N. H., Octavia, S., & Teo, J. W. P. (2023) · Microbial Genomics · doi:10.1099/mgen.0.001047 · Cited by 17
“…single amino acid substitutions in PDR1p , F575L, P822L and have been shown in separate studies to increase the expression of CDR1 thus contributing to azole resistance of clinical isolates [29], we observed shared polymorphisms in both our azole-susceptible and azole-resistant isolates (Table S7).”
Molecular epidemiology and antimicrobial resistance of vaginal Candida glabrata isolates in Namibia
Dunaiski, C. M., Kock, M. M., Chan, W. Y., Ismail, A., & Peters, R. P. H. (2024) · Medical Mycology · doi:10.1093/mmy/myae009 · Cited by 12
Daneshnia, F., Polat, S. H., İlkit, M., Shor, E., de Almeida, J. N., Favarello, L. M., Colombo, A. L., Arastehfar, A. A., & Perlin, D. S. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.906681 · Cited by 12
Paul, S. K., McDonald, W. H., & Moye-Rowley, S. (2018) · Molecular Microbiology · doi:10.1111/mmi.14109 · Cited by 11
“glabrata, mutational alterations in PDR1 (Ferrari et al., 2009), direct binding of azoles and other drugs (Thakur et al.”
BackgroundBhakt, P., Shivarathri, R., Choudhary, D. K., Borah, S., & Kaur, R. (2018) · Molecular Microbiology · doi:10.1111/mmi.14110 · Cited by 14
“We expressed the CgPDR1 hyperactive allele, containing L280F mutation in its regulatory domain (Ferrari et al., 2009; Borah et al., 2014), in Cgfab1Δ cells, and checked growth in the fluconazole medium.”
BackgroundNonidentical function of Upc2A binding sites in the Candida glabrata CDR1 promoter
Vu, B. G., & Moye-Rowley, S. (2022) · Genetics · doi:10.1093/genetics/iyac135 · Cited by 11
Huang, S., Song, Y., Lv, G., Liu, J., Zhao, J., Wang, L.-L., & Xiang, M.-J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1550894 · Cited by 13
Hull, C. M., Purdy, N. J., & Moody, S. C. (2014) · Future Microbiology · doi:10.2217/fmb.13.160 · Cited by 11
Navarro-Rodríguez, P., Martín‐Vicente, A., López‐Fernández, L., Guarro, J., & Capilla, J. (2019) · Medical Mycology · doi:10.1093/mmy/myz014 · Cited by 12
A homologous overexpression system to study roles of drug transporters in Candida glabrata
Kumari, S., Kumar, M., Khandelwal, N., Pandey, A. K., Bhakt, P., Kaur, R., Prasad, R., & Gaur, N. A. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa032 · Cited by 9
What ‘Omics can tell us about antifungal adaptation
Ribeiro, G. F., Denes, E., Heaney, H., & Childers, D. S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab070 · Cited by 11
“CgPDR1 also affects the expression of the adhesin EPA1, and PDR1 GOF mutations have been associated with increased adherence to epithelial cells and enhanced virulence in mouse candidemia models (Ferrari et al. 2009; Vale-Silva et al. 2016).”
BackgroundPuri, N., Manoharlal, R., Sharma, M., Sanglard, D., & Prasad, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.123 · Cited by 9
Self-citationAdvancing Antimicrobial Resistance Research Through Quantitative Modeling and Synthetic Biology
Farquhar, K. S., Flohr, H., & Charlebois, D. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.583415 · Cited by 9
“Furthermore, it is known that mutations in PDR1, a gene that regulates PDR5 in the pleiotropic drug resistance (PDR) network in yeast (Figure 2A), can cause full resistance to the antifungal drug fluconazole (Ferrari et al., 2009).”
BackgroundChemogenomic profiling to understand the antifungal action of a bioactive aurone compound
Alqahtani, F. M., Arivett, B. A., Taylor, Z. E., Handy, S. T., Farone, A. L., & Farone, M. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226068 · Cited by 10
“glabrata is resistant to azole drugs due to ~67 gain of function mutations in the transcriptional factor CgPDR1 gene, resulting in overexpression of CgCDR1/2-encoded efflux pumps [76].”
BackgroundKołaczkowska, A., Dyląg, M., & Kołaczkowski, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.047 · Cited by 9
Nickels, T. J., & Cunningham, K. W. (2025) · mSphere · doi:10.1128/msphere.00270-25 · Cited by 8
“A variety of GOF mutants of PDR1 have been isolated from azole-treated patients that appear to bypass the requirement for upstream signals that emanate from dysfunctional mitochondria (29).”
Spettel, K., Bumberger, D., Kriz, R., Frank, S., Loy, M., Galazka, S., Suchomel, M., Lagler, H., Makristathis, A., & Willinger, B. (2025) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-024-01511-4 · Cited by 9
Oxidative stress response and virulence factors in Candida glabrata clinical isolates
Berila, N., Hyroššová, P., & Šubík, J. (2011) · Folia Microbiologica · doi:10.1007/s12223-011-0016-2 · Cited by 12
“Secretion of proteinases and phospholipases (Mohan and Ballal 2008) as well as gain-of-function mutations in the CgPDR1 gene, resulting in resistance to multiple drugs, also enhances the virulence (Ferrari et al. 2009).”
BackgroundKumari, S., Kumar, M., Esquivel, B. D., Wasi, M., Pandey, A. K., Khandelwal, N., Mondal, A. K., White, T. C., Prasad, R., & Gaur, N. A. (2022) · mBio · doi:10.1128/mbio.03545-21 · Cited by 9
Azole Antifungal Drugs: Mode of Action and Resistance
Garcia‐Rubio, R., Monteiro, M. C., & Mellado, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20731-0 · Cited by 9
Bohner, F., Papp, C., Takács, T., Varga, M., Szekeres, A., Nosanchuk, J. D., Vágvölgyi, C., Tóth, R., & Gácser, A. (2023) · Journal of Fungi · doi:10.3390/jof9121148 · Cited by 10
“These studies suggests that, in general, the development of triazole resistance attenuates virulence as an effect of a related fitness trade-off, although in some cases, the virulence of resistant strains is enhanced, further complicating the effective treatment of associated infections [42,43].”
BackgroundMo, X., Yu, X., Cui, H., Xiong, K., Yang, S., Su, C., & Lü, Y. (2024) · mSphere · doi:10.1128/msphere.00715-24 · Cited by 10
“Tissue fungal burdens were measured 4 days after infection in the immunosup pressed mice using tail-vein injections according to the previously established protocol (32).”
Hybrid adaptation is hampered by Haldane’s sieve
Bautista, C., Gagnon-Arsenault, I., Utrobina, M., Fijarczyk, A., Bendixsen, D. P., Stelkens, R., & Landry, C. R. (2024) · Nature Communications · doi:10.1038/s41467-024-54105-4 · Cited by 7
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch130 · Cited by 9
Metadata
- Authors
- Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- GATC Biotech (Germany) (DE)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Sanglard, Dominique
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-01-16
- Volume
- 5
- Issue
- 1
- Pages
- e1000268
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2607542
- OpenAlex
- W2133189384
- Cited by
- 295
- References
- 46
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 19 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 25 · 2017: 19 · 2016: 17 · 2015: 12 · 2014: 22 · 2013: 18 · 2012: 14
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, gain-of-function mutations, azole resistance, antifungal resistance, virulence, ABC transporters, transcription factors, clinical isolates, host fitness, trans-acting regulation
- MeSH terms
- Animals, Candidiasis, Female, Humans, Mice, Inbred BALB C, Mutation, Transcription Factors, Virulence, Fluconazole, Gene Expression Regulation, Fungal, ATP-Binding Cassette Transporters, Amino Acid Substitution, Drug Resistance, Fungal, Candida glabrata, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.